Skip to content

ANTI-INFLAMMATORY EFFECT OF KALARCHIKAI AMONG INDIVIDUALS WITH TYPE II DIABETES: A RANDOMIZED CONTROLLED TRIAL

ANTI-INFLAMMATORY EFFECT OF CAESALPINIA CRISTA AMONG INDIVIDUALS WITH TYPE II DIABETES MELLITUS: A RANDOMIZED CONTROLLED TRIAL - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084506
Enrollment
60
Registered
2025-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Caesalpinia crista powder mixed in tepid water and taken on an empty stomach every morning for 4 weeks: Initially inner seeds are extracted by removing the outer coat. The extracted see

Sponsors

Dr Srivathsan R
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age: 30 to 65 years. 2) Both males and females. 3) Subjects with type 2 diabetes mellitus meeting the American Diabetic Association diagnostic criteria and those who are on oral anti-diabetic therapy

Exclusion criteria

Exclusion criteria: 1) Type 2 diabetes mellitus individuals with hypertension. 2) Chronic kidney or liver failure. 3) Pregnant and lactating women 4) Subject with drug or substance abuse 5) Rash or open wounds on the limbs. 6) Subjects who are Underweight and with morbid obesity. 7) T2DM individuals with emaciation or established CAD or any organic vascular disease, neurological / thyroid disorders, nutritional disorders, insulin therapy, and any other acute illness.

Design outcomes

Primary

MeasureTime frame
1) NLR and PLR ratio and MPV 2) Fasting blood glucose level 3) Postprandial blood glucose level Timepoint: Day 0- Collection of pre data Day 1 to day 28- Interventional period Day 29- Collection of post data

Secondary

MeasureTime frame
1) white blood cell count (WBC), mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), platelet count.Timepoint: Day 0- Collection of pre data Day 1 to day 28- Interventional period Day 29- Collection of post data

Countries

India

Contacts

Public ContactDr Srivathsan R

SDM College of Naturopathy and yogic Sciences

drprashanth9@gmail.com9448252696

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026